Table 4 Circulatory support and postoperative outcome related to incremental quartiles of NT-proBNP on POD1
NT-proBNP POD1 < 1324 ng/L (n = 80) | NT-proBNP POD1 ≥ 1324 ng/L to < 2065 ng/L (n = 80) | NT-proBNP POD1 ≥ 2065 ng/L to < 3650 ng/L (n = 80) | NT-proBNP POD1 ≥ 3650 ng/L (n = 80) | p value | |
|---|---|---|---|---|---|
PHF | 1% (1) | 11% (9) | 8% (6) | 19% (15) | 0.002 |
Severe PHF | 0 | 0 | 3% (2) | 6% (5) | 0.02 |
Use of Inotrope | 10% (8) | 20% (16) | 23% (18) | 43% (34) | < 0.0001 |
Use of IABP | 0 | 0 | 1% (1) | 1% (1) | 0.57 |
Duration of inotropic treatment a(h) | 1.0 ± 3.9 | 6.3 ± 20.4 | 9.0 ± 26.4 | 19.1 ± 42.5 | < 0.0001 |
Duration of inotropic treatment b(h) | 10.1 ± 8.1 | 31.6 ± 36.6 | 39.9 ± 44.0 | 44.9 ± 56.0 | 0.21 |
Duration of inotropic treatment > 24 h | 0 | 6% (5) | 11% (9) | 20% (16) | < 0.0001 |
More than one Inotrope at the same time | 1% (1) | 3% (2) | 5% (4) | 10% (8) | 0.045 |
Adrenalin used | 9% (7) | 18% (14) | 21% (17) | 33% (26) | 0.002 |
Milrinone used | 4% (3) | 8% (6) | 8% (6) | 28% (14) | 0.016 |
Levosimendan used | 0 | 0 | 1% (1) | 5% (4) | 0.031 |
Troponin T POD3 (ng/L) | 180 [110–280] | 250 [140–355] | 220 [130–600] | 450 [200–725] | < 0.0001 |
Delta Troponin T POD3-Pre (ng/L) | 140 [58–230] | 190 [110–350] | 170 [80–430] | 300 [135–520] | 0.001 |
ICU stay (h) | 19.1 ± 10.5 | 22.8 ± 16.7 | 23.5 ± 21.5 | 53.1 ± 101.1 | 0.002 |
ICU stay > 72 h | 0 | 4% (3) | 3% (2) | 13% (10) | 0.001 |
Ventilation time (h) | 4.4 ± 4.5 | 5.3 ± 5.9 | 6.7 ± 18.1 | 28.9 ± 93.2 | 0.001 |
Ventilation time > 48 h | 0 | 0 | 1% (1) | 10% (8) | < 0.0001 |
AKI | 8% (6) | 4% (3) | 13% (10) | 30% (24) | < 0.0001 |
Postoperative stroke | 1% (1) | 0 | 1% (1) | 1% (1) | 0.8 |
Hospital mortality | 0 | 0 | 3% (2) | 4% (3) | 0.14 |